

Drug	Schedule
Ecgonine (9180) .....	II
Ethylmorphine (9190) .....	II
Hydrocodone (9193) .....	II
Levorphanol (9220) .....	II
Meperidine (9230) .....	II
Methadone (9250) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Opium, powdered (9639) .....	II
Levo-alphaacetylmethadol (9648) .....	II
Oxymorphone (9652) .....	II
Fentanyl (9801) .....	II

The company plans to import the listed controlled substances for sale to research facilities for drug testing and analysis.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Sigma Aldrich Manufacturing LLC. to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Sigma Aldrich Manufacturing LLC. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: April 15, 2011.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of  
Diversion Control, Drug Enforcement  
Administration.

[FR Doc. 2011-10145 Filed 4-26-11; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 31, 2011, Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by letter to the Drug Enforcement Administration

(DEA) to be registered as a bulk manufacturer of 4-Anilino-N-phenethyl-4-Piperidine (8333), a basic class of controlled substance listed in schedule II.

The company plans to use this controlled substance in the manufacture of another controlled substance.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than June 27, 2011.

Dated: April 15, 2011.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of  
Diversion Control, Drug Enforcement  
Administration.

[FR Doc. 2011-10139 Filed 4-26-11; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated October 6, 2010, and published in the **Federal Register** on October 14, 2010, 75 FR 63203, PCAS-Nanosyn, LLC, 3331-B Industrial Drive, Santa Rosa, California 95403, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Methylphenidate (1724) .....	II
Phencyclidine (7471) .....	II
Codeine (9050) .....	II

Drug	Schedule
Diprenorphine (9058) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Hydrocodone (9193) .....	II
Methadone (9250) .....	II
Morphine (9300) .....	II
Oxymorphone (9652) .....	II
Fentanyl (9801) .....	II

The company is a contract manufacturer. At the request of the company's customers, it manufactures derivatives of controlled substances in bulk form only. The primary service provided by the company to its customers is the development of the process of manufacturing the derivative. As part of its service to its customers, the company distributes the derivatives of the controlled substances it manufactures to those customers. The company's customers use the newly-created processes and the manufactured derivatives in furtherance of formulation processes and dosage form manufacturing; pre-clinical studies, including toxicological studies; clinical studies supporting investigational Drug Applications; and use in stability studies.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of PCAS-Nanosyn, LLC to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated PCAS-Nanosyn, LLC to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of

the basic classes of controlled substances listed.

Dated: April 15, 2011.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of  
Diversion Control, Drug Enforcement  
Administration.

[FR Doc. 2011-10144 Filed 4-26-11; 8:45 am]

BILLING CODE 4410-09-P

## NUCLEAR REGULATORY COMMISSION

[Docket No. NRC-2010-0377]

### Agency Information Collection Activities: Submission for the Office of Management and Budget (OMB) Review; Comment Request

**AGENCY:** Nuclear Regulatory  
Commission (NRC).

**ACTION:** Notice of the OMB review of  
information collection and solicitation  
of public comment.

**SUMMARY:** The NRC has recently  
submitted to OMB for review the  
following proposal for the collection of  
information under the provisions of the  
Paperwork Reduction Act of 1995 (44  
U.S.C. Chapter 35). The NRC hereby  
informs potential respondents that an  
agency may not conduct or sponsor, and  
that a person is not required to respond  
to, a collection of information unless it  
displays a currently valid OMB control  
number. The NRC published a **Federal  
Register** Notice with a 60-day comment  
period on this information collection on  
December 23, 2010.

1. *Type of submission, new, revision,  
or extension:* Extension.

2. *The title of the information  
collection:* NUREG/BR-0238, Materials  
Annual Fee Billing Handbook; NRC  
Form 628, "Financial EDI  
Authorization;" NUREG/BR-0254,  
Payment Methods; and NRC Form 629,  
"Authorization for Payment by Credit  
Card."

3. *Current OMB approval number:*  
3150-0190.

4. *The form number if applicable:*  
NRC Form 628, "Financial EDI  
Authorization" and NRC Form 629,  
"Authorization for Payment by Credit  
Card."

5. *How often the collection is  
required:* On occasion (as needed to pay  
invoices).

6. *Who will be required or asked to  
report:* Anyone doing business with the  
Nuclear Regulatory Commission  
including licensees, applicants and  
individuals who are required to pay a  
fee for inspections and licenses.

7. *An estimate of the number of  
annual responses:* 583 (11 for NRC form

628 and 572 for NRC form 629 and  
NUREG/BR-0254).

8. *The estimated number of annual  
respondents:* 583 (11 for NRC form 628  
and 572 for NRC form 629 and NUREG/  
BR-0254).

9. *An estimate of the total number of  
hours needed annually to complete the  
requirement or request:* 47 hours (.9  
hour for NRC form 628 and 46 hours for  
NRC form 629 and NUREG/BR-0254).

10. *Abstract:* The U.S. Department of  
the Treasury encourages the public to  
pay monies owed the government  
through use of the Automated  
Clearinghouse Network and credit  
cards. These two methods of payment  
are used by licensees, applicants, and  
individuals to pay civil penalties, full  
cost licensing fees, and inspection fees  
to the NRC.

The public may examine and have  
copied for a fee publicly available  
documents, including the final  
supporting statement, at the NRC's  
Public Document Room, Room O-1F21,  
One White Flint North, 11555 Rockville  
Pike, Rockville, Maryland 20852. OMB  
clearance requests are available at the  
NRC worldwide Web site: [http://  
www.nrc.gov/public-involve/doc-  
comment/omb/](http://www.nrc.gov/public-involve/doc-comment/omb/). The document will be  
available on the NRC home page site for  
60 days after the signature date of this  
notice.

Comments and questions should be  
directed to the OMB reviewer listed  
below by May 27, 2011. Comments  
received after this date will be  
considered if it is practical to do so, but  
assurance of consideration cannot be  
given to comments received after this  
date.

Christine J. Kymn, Desk Officer,  
Office of Information and Regulatory  
Affairs (3150-0190), NEOB-10202,  
Office of Management and Budget,  
Washington, DC 20503.

Comments can also be e-mailed to  
[Christine.J.Kymn@omb.eop.gov](mailto:Christine.J.Kymn@omb.eop.gov) or  
submitted by telephone at 202-395-  
4638.

The NRC Clearance Officer is  
Tremaine Donnell, 301-415-6258.

Dated at Rockville, Maryland, this 21st day  
of April, 2011.

For the Nuclear Regulatory Commission.

**Tremaine Donnell,**

NRC Clearance Officer, Office of Information  
Services.

[FR Doc. 2011-10162 Filed 4-26-11; 8:45 am]

BILLING CODE 7590-01-P

## NUCLEAR REGULATORY COMMISSION

[Docket No. NRC-2011-0056]

### Agency Information Collection Activities: Proposed Collection; Comment Request

**AGENCY:** Nuclear Regulatory  
Commission (NRC).

**ACTION:** Notice of pending NRC action to  
submit an information collection  
request to the Office of Management and  
Budget (OMB) and solicitation of public  
comment.

**SUMMARY:** The NRC invites public  
comment about our intention to request  
the OMB's approval for renewal of an  
existing information collection that is  
summarized below. We are required to  
publish this notice in the **Federal  
Register** under the provisions of the  
Paperwork Reduction Act of 1995 (44  
U.S.C. Chapter 35).

Information pertaining to the  
requirement to be submitted:

1. *The title of the information  
collection:* 10 CFR part 81, "Standard  
Specifications for Granting of Patent  
Licenses."

2. *Current OMB approval number:*  
3150-0121.

3. *How often the collection is  
required:* Applications for licenses are  
submitted once. Other reports are  
submitted annually or as other events  
require.

4. *Who is required or asked to report:*  
Applicants for and holders of NRC  
licenses to NRC inventions.

5. *The number of annual respondents:*  
1.

6. *The number of hours needed  
annually to complete the requirement or  
request:* 37; however, no applications  
are anticipated during the next 3 years.

7. *Abstract:* As specified in 10 CFR  
part 81, the NRC may grant non-  
exclusive licenses or limited exclusive  
licenses to its patent inventions to  
responsible applicants. Applicants for  
licenses to NRC inventions are required  
to provide information which may  
provide the basis for granting the  
requested license. In addition, all  
license holders must submit periodic  
reports on efforts to bring the invention  
to a point of practical application and  
the extent to which they are making the  
benefits of the invention reasonably  
accessible to the public. Exclusive  
license holders must submit additional  
information if they seek to extend their  
licenses, issue sublicenses, or transfer  
the licenses. In addition, if requested,  
exclusive license holders must promptly  
supply to the United States Government  
copies of all pleadings and other papers